Taken together, our results show that WKYMVm ameliorates obesity by improving lipid metabolism and leptin signalling, suggesting that WKYMVm can be a useful molecule for the development of anti‐obesity agents. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.